Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 31, 2026, 6:47 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1153–1176 of 1,471 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Safety Testing Clear all
Completed Not applicable Interventional Results available

Early Feasibility Study 2 of Outpatient Control-to-Range - Testing System Efficacy

NCT01714505
View directory record Official record
Conditions
Diabetes Mellitus, Type 1
Interventions
Diabetes Assistant (DiAs)
Device
Lead sponsor
University of Virginia
Other
Eligibility
21 Years to 64 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
2
States / cities
Santa Barbara, California • Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Sep 9, 2014 · Synced Oct 31, 2026, 6:47 PM EDT
Completed Phase 2 Interventional Results available

Long-Term Extension of Previous rAvPAL-PEG Protocols in Subjects With PKU (PAL-003)

NCT00924703
View directory record Official record
Conditions
Phenylketonuria
Interventions
rAvPAL-PEG
Drug
Lead sponsor
BioMarin Pharmaceutical
Industry
Eligibility
16 Years to 55 Years
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2019
U.S. locations
14
States / cities
Aurora, Colorado • Gainesville, Florida • Chicago, Illinois + 11 more
Source: ClinicalTrials.gov public record
Updated Oct 12, 2021 · Synced Oct 31, 2026, 6:47 PM EDT
Completed Phase 1 Interventional

Pilot Test of ACTOS in Multiple Sclerosis: Safety and Tolerability

NCT00242177
View directory record Official record
Conditions
Multiple Sclerosis, Relapsing-Remitting
Interventions
ACTOS (Pioglitazone)
Drug
Lead sponsor
University of Illinois Chicago
Other
Eligibility
18 Years to 65 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2005
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jul 22, 2019 · Synced Oct 31, 2026, 6:47 PM EDT
Not listed Not applicable Interventional

Evaluation of the Safety and Effectiveness of the Dexcom Glucose Monitoring (CGM) System

NCT04645641
View directory record Official record
Conditions
Diabetes Mellitus
Interventions
Continuous Glucose Monitoring System
Device
Lead sponsor
DexCom, Inc.
Industry
Eligibility
2 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
4
States / cities
Escondido, California • Aurora, Colorado • Idaho Falls, Idaho + 1 more
Source: ClinicalTrials.gov public record
Updated Nov 27, 2020 · Synced Oct 31, 2026, 6:47 PM EDT
Terminated Phase 2Phase 3 Interventional Results available

A Study to Test Long-term Treatment With Spesolimab in People With a Skin Condition Disease Called Hidradenitis Suppurativa (HS) Who Took Part in a Previous Study With Spesolimab

NCT06241573
View directory record Official record
Conditions
Hidradenitis Suppurativa (HS)
Interventions
Spesolimab, Placebo
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
4
States / cities
Fountain Valley, California • Los Angeles, California • Sacramento, California + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 17, 2026 · Synced Oct 31, 2026, 6:47 PM EDT
Recruiting Phase 2 Interventional

An Extension Trial to Test if TEV-56286 is Effective in Relieving Multiple System Atrophy

NCT07197866
View directory record Official record
Conditions
Multiple System Atrophy
Interventions
TEV-56286
Drug
Lead sponsor
Teva Branded Pharmaceutical Products R&D LLC
Industry
Eligibility
30 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
10
States / cities
La Jolla, California • Boca Raton, Florida • Tampa, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Oct 9, 2026 · Synced Oct 31, 2026, 6:47 PM EDT
Terminated Phase 2 Interventional Results available

Effects of Inhaled Treprostinil Sodium for the Treatment of Pulmonary Hypertension Associated With Idiopathic Pulmonary Fibrosis

NCT00703339
View directory record Official record
Conditions
Idiopathic Pulmonary Fibrosis, Pulmonary Hypertension
Interventions
Treprostinil sodium for inhalation
Drug
Lead sponsor
Lung Biotechnology PBC
Industry
Eligibility
35 Years to 80 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
6
States / cities
La Jolla, California • Sacramento, California • Ann Arbor, Michigan + 3 more
Source: ClinicalTrials.gov public record
Updated May 11, 2018 · Synced Oct 31, 2026, 6:47 PM EDT
Completed Not applicable Interventional Results available

Safety and Feasibility Testing of a Smaller Network Version of AIDANET

NCT06633965
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
AIDANET
Device
Lead sponsor
Marc Breton
Other
Eligibility
18 Years to 60 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Aug 14, 2025 · Synced Oct 31, 2026, 6:47 PM EDT
Active, not recruiting Phase 1 Interventional

Evaluate the Safety, Immunologic, and Virologic Responses of Donor Derived (DD) HIV-Specific T-cells (HST) in HIV-infected Individuals Following Allogeneic Bone Marrow Transplantation (alloRESIST)

NCT04248192
View directory record Official record
Conditions
HIV-Infected Individuals
Interventions
DD HST-NEETs
Biological
Lead sponsor
Catherine Bollard
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 14, 2026 · Synced Oct 31, 2026, 6:47 PM EDT
Terminated No phase listed Observational Accepts healthy volunteers

Alcohol and Bariatric Surgery

NCT02766322
View directory record Official record
Conditions
Obesity
Interventions
Oral Alcohol challenge test Alcohol visit first, Oral Alcohol challenge test Placebo visit first, Intravenous Alcohol Challenge Test (Clamp), Intravenous Alcohol Self-administration Test
Other
Lead sponsor
University of Illinois at Urbana-Champaign
Other
Eligibility
21 Years to 64 Years · Female only
Enrollment
54 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2022
U.S. locations
1
States / cities
Urbana, Illinois
Source: ClinicalTrials.gov public record
Updated Mar 11, 2025 · Synced Oct 31, 2026, 6:47 PM EDT
Recruiting Phase 1 Interventional

A Study of the Safety, Dosing, and Delivery of NEO100 in Patients With Pediatric Brain Tumors

NCT06357377
View directory record Official record
Conditions
Pediatric Tumor of CNS, Pediatric Tumor of Brain, Diffuse Midline Glioma, H3 K27M-Mutant, Pediatric Tumor of Brain Stem, Pineocytoma, Choroid Plexus Carcinoma, Childhood, Spinal Cord Tumor, High Grade Glioma
Interventions
NEO100
Drug
Lead sponsor
Neonc Technologies, Inc.
Industry
Eligibility
5 Years to 18 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Orange, California
Source: ClinicalTrials.gov public record
Updated Sep 15, 2026 · Synced Oct 31, 2026, 6:47 PM EDT
Completed Phase 3 Interventional Results available

Open-Label Study of Diclofenac Capsules to Treat Osteoarthritis Pain

NCT01510912
View directory record Official record
Conditions
Osteoarthritis
Interventions
Diclofenac
Drug
Lead sponsor
Iroko Pharmaceuticals, LLC
Industry
Eligibility
40 Years and older
Enrollment
602 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
40
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Anaheim, California + 31 more
Source: ClinicalTrials.gov public record
Updated May 9, 2014 · Synced Oct 31, 2026, 6:47 PM EDT
Terminated Phase 1 Interventional

Study of Tazemetostat in Lymphoid Malignancies

NCT05983965
View directory record Official record
Conditions
T-cell Lymphoma
Interventions
Tazemetostat
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Apr 17, 2026 · Synced Oct 31, 2026, 6:47 PM EDT
Completed Phase 4 Interventional Results available

A Study of Enzyme Replacement Therapy (VPRIV) in People With Type 1 Gaucher Disease Who Were Previously Treated With Substrate Reduction Therapy

NCT04718779
View directory record Official record
Conditions
Gaucher Disease
Interventions
Digital Engagement Application (GD App), No Intervention
Other
Lead sponsor
Takeda
Industry
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Fairfax, Virginia
Source: ClinicalTrials.gov public record
Updated Dec 21, 2023 · Synced Oct 31, 2026, 6:47 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Comparison Study of Lay Person Finger Stick Versus Blood Draw

NCT01913145
View directory record Official record
Conditions
Diabetes
Interventions
A1c, Self-collection, Blood sample
Device
Lead sponsor
Home Access Health Corporation
Industry
Eligibility
18 Years to 80 Years
Enrollment
128 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012
U.S. locations
2
States / cities
San Mateo, California • Louisville, Kentucky
Source: ClinicalTrials.gov public record
Updated Apr 21, 2014 · Synced Oct 31, 2026, 6:47 PM EDT
Enrolling by invitation Phase 3 Interventional

A Study Evaluating the Long-Term Efficacy and Safety of Ralinepag in Subjects With PAH Via an Open-Label Extension

NCT03683186
View directory record Official record
Conditions
PAH, Pulmonary Hypertension, Pulmonary Arterial Hypertension, Hypertension, Connective Tissue Diseases, Familial Primary Pulmonary Hypertension, Vascular Diseases, Cardiovascular Diseases, Hypertension, Pulmonary, Lung Diseases, Respiratory Tract Disease
Interventions
Ralinepag
Drug
Lead sponsor
United Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
48
States / cities
Phoenix, Arizona • Tucson, Arizona • La Jolla, California + 38 more
Source: ClinicalTrials.gov public record
Updated Oct 6, 2026 · Synced Oct 31, 2026, 6:47 PM EDT
Suspended Phase 1 Interventional

Trial of ProAgio in Advanced/Metastatic Colorectal Cancer

NCT06867822
View directory record Official record
Conditions
Advanced Colorectal Cancer, Metastatic Colorectal Cancer
Interventions
ProAgio, FOLFIRI, Bevacizumab
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
19 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Oct 2, 2026 · Synced Oct 31, 2026, 6:47 PM EDT
Recruiting Phase 1 Interventional

Testing for Safety and Colorectal Cancer Preventive Effects of ONC201

NCT05630794
View directory record Official record
Conditions
Colorectal Adenomatous Polyp, Colorectal Carcinoma, Familial Adenomatous Polyposis, Multiple Adenomatous Polyps
Interventions
Biopsy Procedure, Biospecimen Collection, Colonoscopy, Dordaviprone Hydrochloride, Endoscopic Procedure, Questionnaire Administration, Sigmoidoscopy
Procedure · Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
5
States / cities
Ann Arbor, Michigan • St Louis, Missouri • Cleveland, Ohio + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 15, 2026 · Synced Oct 31, 2026, 6:47 PM EDT
Recruiting Not applicable Interventional

ROME GS System Study

NCT07518004
View directory record Official record
Conditions
Diabetes, Diabetes Melletus, Type 1, Diabetes Mellitus, Type 2
Interventions
Continuous Glucose Monitoring System
Device
Lead sponsor
Senseonics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
4
States / cities
Escondido, California • Walnut Creek, California • San Antonio, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 21, 2026 · Synced Oct 31, 2026, 6:47 PM EDT
Active, not recruiting Not applicable Interventional Results available

PRE-ProstAtectomy MRI-GuidEd Stereotactic Body RadioTherapy for High-Risk Prostate Cancer Trial (PREPARE SBRT)

NCT03663218
View directory record Official record
Conditions
Prostate Cancer
Interventions
5 Gy x 5 fractions, 6 Gy x 5 fractions, 6.5 Gy x 5 fractions, maximum tolerated dose (6.5 Gy x 5 fractions), recommended phase 2 dose (6.5 Gy x 5 fractions)
Radiation
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years to 90 Years · Male only
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2027
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 18, 2026 · Synced Oct 31, 2026, 6:47 PM EDT
Completed Phase 3 Interventional Results available

To Compare the Safety and Efficacy of Perrigo's Product to an FDA Approved Product for the Treatment of Glaucoma or Ocular Hypertension in Both Eyes

NCT04024072
View directory record Official record
Conditions
Glaucoma, Open-Angle, Ocular Hypertension
Interventions
Brinzolamide 1% ophthalmic suspension, Azopt 1% Ophthalmic Suspension
Drug
Lead sponsor
Padagis LLC
Industry
Eligibility
18 Years and older
Enrollment
495 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 6, 2023 · Synced Oct 31, 2026, 6:47 PM EDT
Completed Not applicable Interventional

Cardiac Rehabilitation Program in Peripheral Arterial Disease

NCT03251391
View directory record Official record
Conditions
Peripheral Arterial Disease
Interventions
Cardiac Rehabilitation Program, Conventional Therapy
Other
Lead sponsor
University of Kansas Medical Center
Other
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated Sep 6, 2019 · Synced Oct 31, 2026, 6:47 PM EDT
Completed Not applicable Interventional

Automated Insulin Delivery (AID) for Basal Insulin Titration in Type 2 Diabetes

NCT06024928
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
Control-IQ use in Type 2 Diabetes under basal insulin injections
Device
Lead sponsor
University of Virginia
Other
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated May 14, 2026 · Synced Oct 31, 2026, 6:47 PM EDT
Completed Phase 3 Interventional

Study to Evaluate the Safety and Bioequivalence of Estradiol Vaginal Inserts, 10 mcg and Vagifem® 10 mcg and Compare to Placebo

NCT01779947
View directory record Official record
Conditions
Atrophic Vaginitis Due to Menopause
Interventions
Estradiol Vaginal Tablets 10 mcg, placebo
Drug
Lead sponsor
Amneal Pharmaceuticals, LLC
Industry
Eligibility
30 Years to 75 Years · Female only
Enrollment
519 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012
U.S. locations
25
States / cities
Huntsville, Alabama • Montgomery, Alabama • San Diego, California + 19 more
Source: ClinicalTrials.gov public record
Updated Jun 26, 2014 · Synced Oct 31, 2026, 6:47 PM EDT